Myrtucommulone from Myrtus communis: Metabolism, Permeability, and Systemic Exposure in Rats

Abstract

Nonsteroidal anti-inflammatory drug intake is associated with a high prevalence of gastrointestinal side effects, and severe cardiovascular adverse reactions challenged the initial enthusiasm in cyclooxygenase-2 inhibitors. Recently, it was shown that myrtucommulone, the active ingredient of the Mediterranean shrub Myrtus communis, dually and potently inhibits microsomal prostaglandin E₂ synthase-1 and 5-lipoxygenase, suggesting a substantial anti-inflammatory potential. However, one of the most important prerequisites for the anti-inflammatory effects in vivo is sufficient bioavailability of myrtucommulone. Therefore, the present study was aimed to determine the permeability and metabolic stability in vitro as well as the systemic exposure of myrtucommulone in rats. Permeation studies in the Caco-2 model revealed apparent permeability coefficient values of 35.9 · 10⁻⁶ cm/s at 37 °C in the apical to basolateral direction, indicating a high absorption of myrtucommulone. In a pilot rat study, average plasma levels of 258.67 ng/mL were reached 1 h after oral administration of 4 mg/kg myrtucommulone. We found that myrtucommulone undergoes extensive phase I metabolism in human and rat liver microsomes, yielding hydroxylated and bihydroxylated as well as demethylated metabolites. Physiologically-based pharmacokinetic modeling of myrtucommulone in the rat revealed rapid and extensive distribution of myrtucommulone in target tissues including plasma, skin, muscle, and brain. As the development of selective microsomal prostaglandin E₂ synthase-1 inhibitors represents an interesting alternative strategy to traditional nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for the treatment of chronic inflammation, the present study encourages further detailed pharmacokinetic investigations on myrtucommulone.

Key words

myrtucommulone - Myrtus communis - Myrtaceae - myrtle - rat plasma - Caco-2 - metabolism - physiologically-based pharmacokinetic modeling

• References

• 1 Abdel-Tawab M, Zettl H, Schubert-Zsilavecz M. Non-steroidal anti-inflammatory drugs: a critical review on current concepts applied to reduce gastrointestinal toxicity. Curr Med Chem 2009; 16: 475-481
• 2 Appendino G, Bianchi F, Minassi A, Sterner O, Ballero M, Gibbons S. Oligomeric acylphloroglucinols from myrtle (Myrtus communis). J Nat Prod 2002; 65: 334-338
• 3 Feißt C, Franke L, Appendino G, Werz O. Identification of molecular targets of the oligomeric nonprenylated acylphloroglucinols from Myrtus communis and their implication as anti-inflammatory compounds. J Pharm Exp Ther 2005; 315: 389-396
• 4 Bonjar GH. Antibacterial screening of plants used in Iranian folkloric medicine. Fitoterapia 2004; 75: 231-235
• 5 Elfellah MS, Akhter MH, Khan MT. Anti-hyperglycaemic effect of an extract of Myrtus communis in streptozotocin-induced diabetes in mice. J Ethnopharmacol 1984; 11: 275-281
• 6 Sepici A, Gürbüz I, Cevik C, Yesilada E. Hypoglycaemic effects of myrtle oil in normal and alloxan-diabetic rabbits. J Ethnopharmacol 2004; 93: 311-318
• 7 Levesque H, Lafont O. Aspirin throughout the ages: a historical review. Rev Med Interne 2000; 21 (Suppl. 01) 8s-17s
• 8 Hayder N, Abdelwahed A, Kilani S, Ammar RB, Mahmoud A, Ghedira K, Chekir-Ghedira L. Anti-genotoxic and free-radical scavenging activities of extracts from (Tunisian) Myrtus communis . Mutat Res 2004; 564: 89-95
• 9 Romani A, Coinu R, Carta S, Pinelli P, Galvardi C, Vincieri FF, Franconi F. Evaluation of antioxidant effect of different extracts of Myrtus communis L. Free Radic Res 2004; 38: 97-103
• 10 Rosa A, Deiana M, Casu V, Corona G, Appendino G, Bianchi F, Ballero M, Dessi MA. Antioxidant activity of oligomeric acylphloroglucinols from Myrtus communis L. Free Radic Res 2003; 37: 1013-1019
• 11 Fiorini-Puybaret C, Aries MF, Fabre B, Mamatas S, Luc J, Degouy A, Ambonati M, Mejean C, Poli F. Pharmacological properties of Myrtacine® and its potential value in acne treatment. Planta Med 2011; 77: 1582-1589
• 12 Koeberle A, Pollastro F, Northoff H, Werz O. Myrtucommulone, a natural acylphloroglucinol, inhibits microsomal prostaglandin E(2) synthase-1. Br J Pharmacol 2009; 156: 952-961
• 13 Rossi A, Paola RD, Mazzon E, Genovese T, Caminiti R, Bramanti P, Pergola C, Koeberle A, Werz O, Sautebin L, Cuzzocrea S. Myrtucommulone from Myrtus communis exhibits potent anti-inflammatory effectiveness in vivo . J Pharm Exp Ther 2009; 329: 76-86
• 14 Müller H, Paul M, Hartmann D, Huch V, Blaesius D, Koeberle A, Werz O, Jauch J. Total synthesis of myrtucommulone A. Angew Chem Int Ed 2010; 49: 2045-2049
• 15 Gerbeth K, Meins J, Werz O, Schubert-Zsilavecz M, Abdel-Tawab M. Determination of Myrtucommulone from Myrtus communis in human and rat plasma by liquid chromatography/tandem mass spectrometry. Planta Med 2011; 77: 450-454
• 16 Shah V, Midha KK, Findley JWA, Hill HM, Hulse JD, McGilveray IJ, Mc Kay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A. Bioanalytical method validation – a revisit with a decade of progress. J Pharm Res 2000; 17: 1551-1557
• 17 Edginton AN, Schmitt W, Willmann S. Application of physiology-based pharmacokinetic and pharmacodynamic modeling to individualized target-controlled propofol infusions. Adv Ther 2006; 23: 143-158
• 18 Willmann S, Hoehn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodynam 2007; 34: 401-431
• 19 Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP, Vogelpoel H, Barends DM. Biowaiver monographs for immediate release solid oral dosage forms: Ibuprofen. J Pharm Sci 2005; 94: 2121-2131
• 20 Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestine) absorption in man-fact or myth. Pharm Res 1997; 14: 763-766
• 21 Arthursson P, Karsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880-885
• 22 Jachak SM. PGE synthase inhibitors as an alternative to COX-2 inhibitors. Curr Opin Investig Drugs 2007; 8: 411-415